Abstract
What is Currently Known About the SARS-CoV2 Variants of Concern
Highlights
The UK variant is modestly more resistant to neutralization by sera from individuals who have received the vaccine against SARS-CoV-2 or have recovered from the disease [8]
T cells stimulated by the current vaccines against SARS-CoV-2 that should be able to protect against these new variants, as T cells recognize different parts of the virus
Since COVID-19 vaccines create an immune response to the totality of the spike protein, vaccines should theoretically still be efficacious despite some alterations of antigenic sites in the SARS-CoV-2 variants [12]
Summary
The UK variant is modestly more resistant to neutralization by sera from individuals who have received the vaccine against SARS-CoV-2 or have recovered from the disease [8]. Most of the currently developed vaccines, including Pfizer, Moderna, AstraZeneca, Johnson & Johnson, and Novavax, target the spike protein of the virus, the location of most of the variants’ concerning mutations. T cells stimulated by the current vaccines against SARS-CoV-2 that should be able to protect against these new variants, as T cells recognize different parts of the virus.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
